Article and Video CATEGORIES
Dr. Heather Wakelee, from Stanford University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Please feel free to offer comments and raise questions in our
Next Previous linkPrevious PostNext Post
Hi Caregiver and welcome to Grace. I'm sorry that you need to be here and hope we can help. Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...
Hi Bob, Welcome to Grace. I'm sorry about your sil. Unfortunately, cancer becomes resistant to TKIs like tagrisso. Sometimes all of the cancer becomes resistant at once and sometimes just parts...